Virtual reality could help black men navigate prostate cancer diagnosis

NCT ID NCT07126548

Not yet recruiting Symptom relief Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a virtual reality assistant called ViRA designed to provide emotional support and help with daily needs like food and transportation for Black men recently diagnosed with prostate cancer. About 200 participants will use the ViRA app and researchers will measure how many men enroll, accept, and regularly use the tool. The goal is to see if this approach can help close the care gap for African American men facing prostate cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Virtual reality assistant (ViRA) application
What this could lead to: If it works, this could offer a new way to provide emotional support and help with daily needs for Black men facing a new prostate cancer diagnosis.
What could go wrong: This is an early-stage study focused on feasibility and reach, not on curing or treating cancer. It may not show clear benefits for emotional well-being or resource navigation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.